Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2012 by BS Jeon, Seoul National University Hospital.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
BS Jeon, Seoul National University Hospital Identifier:
First received: January 10, 2012
Last updated: January 18, 2012
Last verified: January 2012
  1. In order to observe the benefit, side effects, and patient preference of Mirapex ER when used in once-daily (QD) or twice-daily (BID) dosing
  2. In order to estimate the conversion rate of dopamine agonists into Mirapex ER

Condition Intervention Phase
Parkinson's Disease
Drug: Mirapex ER
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Randomized, Multi-center, Crossover Study to Observe the Effect of Once-daily Mirapex ER® and Twice-daily Mirapex ER® in Patients With Parkinson Disease

Resource links provided by NLM:

Further study details as provided by BS Jeon, Seoul National University Hospital:

Primary Outcome Measures:
  • Patient preference [ Time Frame: 4 months ]
    Overall preference in QD versus BID

Secondary Outcome Measures:
  • Motor complications [ Time Frame: 2 months at each arm ]
    Visual rating scale for off severity, dyskinesia severity Duration - off duration, dyskinesia duration

  • Sleep problems [ Time Frame: 2 months at each arm ]
    Parkinson's disease sleep scale (PDSS) Excessive daytime sleepiness scale(ESS)

  • Motor UPDRS and HY stage [ Time Frame: 2months at each arm ]
  • Side effects [ Time Frame: 2 months at each arm ]
    Rating scale (0~10): Nausea, Dizziness, Somnolence, Headache, Constipation, Dyspepsia, Fatigue, Hallucination, Edema, Dry mouth,Others

  • Patient global impression for improvement [ Time Frame: 2 months at each arm ]
  • Preference in each factor [ Time Frame: 4 months ]
    Preference of QD versus BID in each factor: off duration, off severity, dyskinesia duration, dyskinesia severity, on quality, adverse events, sleep quality, convenience

  • Patient choice [ Time Frame: 4 months ]
    Patient choice in QD or BID Reason for the choice

Estimated Enrollment: 200
Study Start Date: September 2011
Estimated Study Completion Date: October 2012
Estimated Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Group 1
Give QD dose first then BID dosing
Drug: Mirapex ER
Change Requip or Mirapex to Mirapex ER
Active Comparator: Group 2
Give BID dosing and then QD dosing
Drug: Mirapex ER
Change Requip or Mirapex to Mirapex ER

Detailed Description:
  1. Study subjects : Parkinson disease who are on Requip or Mirapex and are considering to change into Mirapex ER
  2. Cross over study design:

    • Group 1: Once daily dose for 2 month then into BID in divided dose for 2 months
    • Group 2: BID in divided dose for 2 months then into QD dose for 2 months
  3. Dose adjustment may be done in the first 4 weeks.
  4. Compare the benefit, side effects, and patient preference between the QD vs BID dosing

Ages Eligible for Study:   30 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age: 30-80
  2. Parkinson disease
  3. On dopamine agonists (Requip or Mirapex) and are considering to change into Mirapex ER
  4. On stable antiparkinsonian medication for at least 4 weeks
  5. Who signed consent to the study

Exclusion Criteria:

  1. Who are on less than 2 mg of Requip or 0.375 mg of Mirapex
  2. Who have dementia, psychosis, major depression and other serious neurological or medical problems
  3. Who are allergic to the similar medications
  4. Who has history of heavy metal poisoning
  5. Who were on othe clinical trials of other medications within the last 4 weeks
  6. Who are pregnant or lactating
  7. Who are considered not eligible by the investigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01515774

Contact: Beom S Jeon, MD, PhD 82-2-2072-2876
Contact: Ji Young Yun, MD 82-2-2072-0359

Korea, Republic of
Seoul National University Hospital Recruiting
Seoul, Korea, Republic of, 110-744
Contact: Beom S. Jeon, MD, PhD    82-2-2072-2876   
Contact: Ji Y Yun, MD    82-2-2072-0359   
Principal Investigator: Beom S. Jeon, MD, PhD         
Sub-Investigator: Han-Joon Kim, MD         
Sub-Investigator: Ji Y Yun, MD         
Sub-Investigator: Young Eun Kim, MD         
Sponsors and Collaborators
Seoul National University Hospital
Principal Investigator: Beom S Jeon, MD, PhD Seoul National University Hospital
  More Information

Responsible Party: BS Jeon, Professor, Seoul National University Hospital Identifier: NCT01515774     History of Changes
Other Study ID Numbers: H-1104-062-358
Study First Received: January 10, 2012
Last Updated: January 18, 2012

Keywords provided by BS Jeon, Seoul National University Hospital:
Parkinson's disease

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents processed this record on May 25, 2017